Study touts Prilosec
This article was originally published in The Tan Sheet
Executive SummaryResults of a study show Procter & Gamble's Prilosec OTC proton-pump inhibitor is comparable in first-day effectiveness to Johnson & Johnson-Merck's histamine-2 receptor antagonist Pepcid AC, but J&J-Merck cites flaws in the P&G-funded study. The study, conducted by the Oklahoma Foundation for Digestive Research, compares the early therapeutic response for PPI (omeprazole) heartburn drugs and H2RAs (famotidine). Researchers, led by Philip Miner, M.D., a clinical professor of medicine at the University of Oklahoma, say they did not expect PPI to work as well as HR2As in the first 24 hours of treatment, but the two drugs showed similar levels of acid suppression during that time. Miner et al. note they did not measure symptom relief or the speed of onset of action, but say both types of drugs "owe their clinical efficacy to their ability to suppress gastric acid secretion." However, J&J-Merck says not measuring actual relief is among the study's flaws, and point out FDA does not accept acid-suppression studies as efficacy evidence...
You may also be interested in...
Brands unfairly maligned by powerful influencers, strictly on behalf of paying competitors, could have occasion to broach the subject with the US Federal Trade Commission, which seeks comment on its “Endorsement Guides” in an increasingly complex and competitive, digitized advertising environment.
At least one FTC commissioner seems convinced that the agency’s Enforcement Guides are ripe for an update to address unscrupulous influencer marketing practices. Democrat Rohit Chopra proposes their codification into formal rules that would make violators liable for civil penalties and damages under FTC Act provisions.
The US agency has suspended all routine surveillance inspections in China through the end of March because of coronavirus fears, commissioner Stephen Hahn announced late on 14 February. Despite expecting medical product shortages, Hahn said the agency is being proactive: “We are not waiting for drug and device manufacturers to report shortages to us” before acting. The timing of Hahn’s statement – at 6 p.m. EST on a Friday, at the beginning of a three-day US holiday weekend – suggests he isn’t particularly excited to share the information.